Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-22T19:24:46.447Z Has data issue: false hasContentIssue false
  • English
  • Français

Preventing Dementia

Published online by Cambridge University Press:  02 December 2014

S.E. Black ,
C. Patterson  and
J. Feightner
S.E. Black
Affiliation:
Department of Medicine, Neurology, University of Toronto, Toronto, Canada
C. Patterson
Affiliation:
Geriatric Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
J. Feightner
Affiliation:
Family Medicine, University of Western Ontario, London, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Primary prevention will become increasingly important as dementia prevalence increases and effective retardive therapies are developed. To date, only one randomized controlled trial (involving treatment of systolic hypertension) has demonstrated that the incidence of dementia can be reduced. Physicians should remain alert to possible secondary causes of dementia and correct these whenever possible. Primary and secondary prevention of stroke should reduce dementia related to cerebrovascular disease either directly or as a comorbid factor in Alzheimer’s disease (AD). Epidemiological studies have revealed a number of risk factors for AD including genetic mutation, susceptibility genes, positive family history, Down’s syndrome, age, sex, years of education, head trauma and neurotoxins. In case-control studies non-steroidal anti-inflammatory medication and estrogen replacement therapy appear to decrease the relative risk of developing AD. Further research to develop and test preventative therapies in AD and other dementias should be strongly encouraged.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 28 , Supplement S1: Canadian Consensus Conference on Dementia , May 2001 , pp. S56 - S66
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

1. Canadian Study of Health and Aging Working Group. Canadianstudy of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899–913.Google Scholar
2. Blass, JP. Pathophysiology of Alzheimer’s syndrome. Neurology 1993;43:S25–S38.Google Scholar
3. American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders. 3 ed. Washington DC: American Psychiatric Association, 1987.Google Scholar
4. Breitner, JC, Welsh, KA. Genes and recent developments in theepidemiology of Alzheimer’s disease and related dementia. [Review]. Epidemiol Rev 1995;17:39–47.CrossRefGoogle Scholar
5. Levy-Lahad, E, Bird, TD. Genetic factors in Alzheimer’s disease: areview of recent advances. Ann Neurol 1996;40:829–840.CrossRefGoogle Scholar
6. Grundman, M, Petersen, RC, Morris, JC, et al. Rate of dementia ofthe Alzheimer type (DAT) in subjects with mild cognitive impairment. Neurology 1996;46:A403(Abstract).Google Scholar
7. Tierney, MC, Szalai, JP, Snow, WG, et al. Prediction of probableAlzheimer’s disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661–665.CrossRefGoogle ScholarPubMed
8. Albert, MS, Jones, K, Savage, CR, et al. Predictors of cognitivechange in older persons: MacArthur studies of successful aging. Psychol Aging 1995;10:578–589.CrossRefGoogle Scholar
9. Ritchie, K, Leibovici, D, Ledesert, B, Touchon, J. A typology ofsubclinical senescent cognitive disorder. Br J Psychiatry 1996;168:470–476.Google Scholar
10. de Leon, MJ, Golomb, J, George, AE, et al. The radiologic predictionof Alzheimer’s disease: The atrophic hippocampal formation. AJNR American Journal of Neuroradiology. 1993;14:897–906.Google Scholar
11. de Leon, MJ, George, AE, Reisberg, B, et al. Alzheimer’s disease:longitudinal CT studies of ventricular change. AJR Am J Roentgenol 1989;152:1256–1262.CrossRefGoogle ScholarPubMed
12. Golomb, J, Kluger, A, de Leon, MJ, et al. Hippocampal formationsize predicts declining memory performance in normal aging. Neurology 1996;47:810–813.Google Scholar
13. Olafsson, K, Jorgensen, S, Jensen, HV, et al. Fluvoxamine in thetreatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatra Scand 1992;85:453–456.Google Scholar
14. Kaye, JA, Swihart, T, Howieson, D, et al. Volume loss of thehippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997;48:1297–1304.CrossRefGoogle Scholar
15. Canadian Study of Health and Aging Working Group. TheCanadian study of health and aging: risk factors for Alzheimer’sdisease in Canada. Neurology 1994;44:2073–2080.Google Scholar
16. Corder, EH, Saunders, AM, Strittmatter, WJ, et al. Gene dose ofapolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.Google Scholar
17. Seshadri, S, Drachman, DA, Lippa, CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer’s disease. What physicians know and what they should know. Arch Neurology 1995;52:1074–1079.Google Scholar
18. Hyman, BT, Gomez-Isla, T, Rebeck, GW, et al. Epidemiological,clinical and neuropathological study of apolipoprotein E genotype in Alzheimer’s disease. Ann NYAcad Sci 1996;802:1–5.CrossRefGoogle ScholarPubMed
19. Poirier, J. Apolipoprotein E in animal models of CNS injury and inAlzheimer’s disease. Trends Neurosci 1994;17:525–530.Google Scholar
20. Roses, AD. Apolipoprotein E and Alzheimer’s disease. A rapidlyexpanding field with medical and epidemiological consequences. Ann NYAcad Sci 1996;802:50–57.Google Scholar
21. Saunders, AM, Strittmatter, WJ, Schmechel, D, et al. Association ofapolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.CrossRefGoogle ScholarPubMed
22. Rosenberg, RN, Richter, RW, Risser, RC, et al. Genetic factors forthe development of Alzheimer ’s disease in the Cherokee Indian. Arch Neurology 1996;53:997–1000.Google Scholar
23. Kurz, A, Altland, K, Lautenschlager, N, et al. Apolipoprotein E type 4 allele and Alzheimer’s disease: effect on age at onset and relative risk in different age groups. J Neurol 1996;243:452 456.Google Scholar
24. Blacker, D, Haines, JL, Rodes, L, et al. ApoE-4 and age at onset ofAlzheimer’s disease: the NIMH genetics initiative. Neurology 1997;48:139–147.Google Scholar
25. Roses, AD. Apolipoprotein E genotyping in the differentialdiagnosis, not prediction, of Alzheimer’s disease. Ann Neurol 1995;38:6–14.Google Scholar
26. van Duijn, CM, Clayton, D, Chandra, V, et al. Familial aggregationof Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20:S13–S20.Google Scholar
27. Wisniewski, KE, Dalton, AJ, Crapper-MacLachlan, DR, Wen, GY,Wisniewski, HM. Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology 1985;35:957–961.Google Scholar
28. Zigman, W, Schupf, N,Haverman, M,Silverman, W. Theepidemiology of Alzheimer’s disease in intellectual disability: results and recommendations from an international conference. JIntellect Disabil Res 1997;41:76–80.Google Scholar
29. Devenny, DA, Silverman, WP, Hill, AL, et al. Normal ageing inadults with Down’s syndrome: a longitudinal study. J Intellect Disabil Res 1996;40:208–221.Google Scholar
30. Zigman, W, Silverman, W,Wisniewski, HM. Aging and Alzheimer’sdisease in Down’s syndrome: clinical and pathological changes. Ment Retard Dev Disabil Res Rev 1996;2:73–79.Google Scholar
31. Visser, FE, Aldenkamp, AP, van Huffelen, AC, et al. Prospectivestudy of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down’s syndrome. Am J Ment Retard 1997;101:400–412.Google Scholar
32. Fratiglioni, L, Viitanen, M, von Strauss, E, et al. Very old women athighest risk of dementia and Alzheimer’s disease: Incidence data from the Kungsholmen Project, Stockholm. Neurology 1997;48:132–138.Google Scholar
33. Friedland, RP. Epidemiology, education and the ecology ofAlzheimer’s disease. Neurology 1993;43:246–249.Google Scholar
34. Stern, Y, Gurland, B, Tatemichi, TK, et al. Influence of education andoccupation on the incidence of Alzheimer’s disease. JAMA 1994;271:1004–1010.Google Scholar
35. Mortimer, JA, van Duijn, CM, Chandra, V, et al. Head trauma as arisk factor for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20:S28–S35.Google Scholar
36. Roberts, GW. Immunocytochemistry of neurofibrillary tangles indementia pugilistica and Alzheimer’s disease: evidence for common genesis. Lancet 1988;2:1456–1458.CrossRefGoogle Scholar
37. Graves, AB, White, E, Koepsell, TD, et al. The association betweenhead trauma and Alzheimer’s disease. Am J Epidemiol 1990;131: 491–501.CrossRefGoogle ScholarPubMed
38. Mayeux, R, Ottman, R, Maestre, G, et al. Synergistic effects oftraumatic head injury and apolipoprotein- epsilon 4 in patients with Alzheimer’s disease. Neurology 1995;45:555–557.Google Scholar
39. Tang, MX, Maestre, G, Tsai, WY, et al. Effect of age, ethnicity andhead injury on the association between ApoE genotypes and Alzheimer’s disease. Ann NYAcad Sci 1996;802:6–15.CrossRefGoogle ScholarPubMed
40. O’Meara, ES, Kukull, WA, Sheppard, L, et al. Head injury and riskof Alzheimer’s disease by apolipoprotein E genotype. Am JEpidemiol 1997;146:373–384.Google Scholar
41. Plassman, BL, Havlik, RJ, Steffens, DC, et al. Documented headinjury in early adulthood and risk of Alzheimer’s disease and other dementias [In Process Citation]. Neurology 2000;55:1158–1166.Google Scholar
42. Mehta, KM, Ott, A, Kalmijn, S, et al. Head trauma and risk ofdementia and Alzheimer’s disease: The Rotterdam Study. Neurology 1999;53:1959–1962.CrossRefGoogle Scholar
43. Lin, WR, Shang, D, Itzhaki, RF. Neurotropic viruses and Alzheimer’sdisease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Mol Chem Neurophathol 1996;28:135–141.Google Scholar
44. Itzhaki, RF, Lin, WR, Shang, D, et al. Herpes simplex virus type 1 inbrain and risk of Alzheimer’s disease. Lancet 1997;349:241–244.Google Scholar
45. Slooter, AJ, Tang, MX, van Duijn, CM, et al. Apolipoprotein Eepsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818–821.Google Scholar
46. Myers, RH, Schaefer, EJ, Wilson, PW, et al. Apolipoprotein Eepsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996;46:673–677.CrossRefGoogle Scholar
47. Martyn, CN, Young, WF, Lacey, RF, Inskip, H, Coggon, DN. Aluminum concentrations in drinking water and risk of Alzheimer’s disease. Epidemiology 1997;8:281–286.Google Scholar
48. Forbes, WF, McLachlan, DR. Further thoughts on the aluminum-Alzheimer’s disease link. J Epidemiol Com Health 1996;50:401–403.Google Scholar
49. Savory, J, Wakayama, I, McLachlan, DR, et al. Can the controversyof the role of aluminum in Alzheimer’s disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? J Toxicol Environ Health 1996;48:615–635.Google Scholar
50. Graves, AB, White, E, Koepsell, TD, et al. The association betweenaluminum-containing products and Alzheimer’s disease. J ClinEpidemiol 1990;43:35–44.Google ScholarPubMed
51. Crapper, DR, Quittkat, S, Krishnan, SS, Dalton, AJ, DeBoni, U. Intranuclear aluminium content in Alzheimer’s disease, dialysis encephalopathy and experimental aluminium encephalopathy. Acta Neuropathol 1980;50:19–24.Google Scholar
52. Rifat, SL, Eastwood, MR, Crapper-MacLachlan, DR, Corey, PN. Effect of exposure of miners to aluminum powder. Lancet 1990;336:1162–1165.CrossRefGoogle Scholar
53. McLachlan, DRC, Bergeron, C, Smith, JE, Boomer, D, Rifat, SL. Riskfor neuropathologically confirmed Alzheimer’s disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996;46:401–405.Google Scholar
54. McLachlan, DRC, Dalton, AJ, Kruck, TPA, et al. Intramusculardesferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304–1308.Google Scholar
55. Brenner, DE, Kukull, WA, van Belle, JD, et al. Relationship betweencigarette smoking and Alzheimer’s disease in a population-based case-control study. Neurology 1993;43:293–300.Google Scholar
56. Lee, PN. Smoking and Alzheimer’s disease: a review of theepidemiological evidence. Neuroepidemiology 1994;13:131–144.Google Scholar
57. Letenneur, L, Dartigues, JF, Commenges, D, et al. To b a c c oconsumption and cognitive impairment in elderly people. A population-based study. Ann Epidemiol 1994;4:449–454.Google Scholar
58. Riggs, JE. The “protective” influence of cigarette smoking onAlzheimer’s and Parkinson’s diseases. Quagmire or opportunity for neuroepidemiology? Neurol Clin 1996;14:353–358.Google Scholar
59. Ott, A, Slooter, AJC, Hofman, A, et al. Smoking and risk of dementiaand Alzheimer’s disease in a population-based cohort study: The Rotterdam study. Lancet 1998;351:1840–1843.Google Scholar
60. McGeer, PL, McGeer, EG. Anti-inflammatory drugs in the fightagainst Alzheimer’s disease. Ann NYAcad Sci 1996;777:213–220.Google Scholar
61. Breitner, JCS. Inflammatory processes and anti-inflamatory drugsin Alzheimer’s disease: a current appraisal. Neurobiol Aging 1996;17:789–794.Google Scholar
62. Aisen, PS, Marin, D, Altstiel, L, et al. A pilot study of prednisone inAlzheimer’s disease. Dementia 1996;7:201–206. Google Scholar
63. Breitner, JC. The role of anti-inflammatory drugs in the preventionand treatment of Alzheimer’s disease. Annu Rev Med 1996;47: 401–411.Google Scholar
64. McGeer, PL, McGeer, E, Rogers, J, Sibley, J. Anti-inflammatorydrugs and Alzheimer’s disease. Lancet 1990;335:1037–1037.Google Scholar
65. Andersen, K, Launer, J, Ott, A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease?The Rotterdam Study. Neurology 1995;45:1441–1445.CrossRefGoogle ScholarPubMed
66. McGeer, PL, Schulzer, M, McGeer, EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996;47:425–432.CrossRefGoogle ScholarPubMed
67. Stewart, WF, Kawas, C, Corrada, M, Metter, EJ. Risk of Alzheimer’sdisease and duration of NSAID use. Neurology 1997;48:626–632.Google Scholar
68. Breitner, JCS, Gau, BA, Welsh, KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994;44:227–232.Google Scholar
69. Rich, JB, Rasmusson, DX, Folstein, MF, et al. Nonsteroidal anti-inflammatory drugs inAlzheimer’sdisease. Neurology 1995;45:51–55.Google Scholar
70. Launer, LJ, Jama, JW, Ott, A, et al. Histamine H2 blocking drugs andthe risk for Alzheimer’s disease: The Rotterdam Study. NeurobiolAging 1997;18:257–259.Google Scholar
71. Bannwarth, B, Demotes-Mainard, F, Schaeverbeke, T, Labat, L, Dehais, J. Central analgesic effects of aspirin-like drugs. FundamClin Pharmacol 1995;9:1–7.Google Scholar
72. Rogers, J, Kirby, LC, Hempelman, SR, et al. Clinical trial of indo-methacin in Alzheimer’s disease. Neurology 1993;43:1609–1611.Google Scholar
73. Scharf, S, Mander, A, Ugoni, A, Vajda, F, Christophidis, N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999;53:197–201.Google Scholar
74. Aisen, PS, Davis, KL, Berg, JD, et al. A randomized controlled trialof prednisone in Alzheimer’s disease. Alzheimer’s DiseaseCooperative Study. Neurology 2000;54:588–593.CrossRefGoogle Scholar
75. Sapolsky, RM, Krey, LC, McEwen, BS. The neuroendocrinology ofstress and aging: the glucocortocoid cascade hypothesis. Epidemiol Rev 1986;7:284–301.Google Scholar
76. Keenan, PA, Jacobson, MW, Soleymani, RM, et al. The effect onmemory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396–1402.Google Scholar
77. Schneider, LS. New therapeutic approaches to Alzheimer’s disease.J Clin Psychiatry 1996;57 Suppl 14:30–36.Google Scholar
78. Toran-Allerand, CD. The estrogen/neurotrophin connection duringneural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996;18:36–48.Google Scholar
79. Behl, C, Widmann, M, Trapp, T, Holsboer, F. 17-b estradiol protectsneurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473–482.Google Scholar
80. Birge, SJ. Is there a role for estrogen replacement therapy in theprevention and treatment of dementia? J Am Geriatr Soc 1996;44:865–870.Google Scholar
81. Sohrabji, F, Miranda, RC, Toran-Allerand, CD. Identification of aputative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995;92: 11110–11114.Google Scholar
82. Gibbs, RB. Estrogen and nerve growth factor-related systems inbrain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann NYAcad Sci 1994;743:165–196; discussion 197–199.Google Scholar
83. Green, PS, Gridley, KE, Simpkins, JW. Estradiol protects againstbeta-amyloid (25–35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 1996;218:165–168.Google Scholar
84. Jaffe, AB, Toran-Allerand, CD, Greengard, P, Gandy, SE. Estrogenregulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994;269:13065–13068.Google Scholar
85. Fink, G, Sumner, BE, Rosie, R, Grace, O, Quinn, JP. Estrogen controlof central neurotransmission: effect on mood, mental state and memory. Cell Mol Neurobiol 1996;16:325–344.Google Scholar
86. Mortel, KF, Meyer, JS. Lack of postmenopausal estrogenreplacement therapy and the risk of dementia. J NeuropsychiatryClin Neurosci 1995;7:334–337.Google Scholar
87. Sherwin BB, Suranyi-Cadotte BE. Up-regulatory effect of estrogenon platelet 3H-Imipramine binding sites in surgically menopausalwomen. Biol Psychiatry 1990;28:339-348.Google Scholar
88. Sherwin, BB. Sex hormones and psychological functioning inpostmenopausal women. Exp Gerontol 1994;29:423–430.Google Scholar
89. Kimura, D, Hampson, E. Cognitive pattern in men and women isinfluenced by fluctuations in sex hormones. Curr Direct Psychol Sci 1994;3:57–61.Google Scholar
90. Sherwin, BB. Estrogenic effects on memory in women. Ann NYAcad Sci 1994;743:213–231.Google Scholar
91. Phillips, SM, Sherwin, BB. Effects of estrogen on memory functionin surgically menopausal women. Psychoneuroendocrinology 1992;17:485–495.Google Scholar
92. Smith CA, Buckwalter JG, Murdock GA, McCleary CA,Henderson VW. Lifetime estrogen exposure and cognitive performance in elderly women. Brain Cogn 1997;(Abstract).Google Scholar
93. Yaffe, K, Sawaya, G, Lieberburg, I, Grady, D. Estrogen therapy inpostmenopausal women. Effects on cognitive function anddementia. JAMA 1998;279:688–695.Google Scholar
94. Szklo, M, Cerhan, J, Diez-Roux, AV, et al. Estrogen replacementtherapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 1996;144:1048–1057.Google Scholar
95. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausalestrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study. Am J Epidemiol 1994; 140:262-267.Google Scholar
96. Henderson, VW, Paganini-Hill, A, Emanuel, CK, Dunn, ME,Buckwalter, JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurology 1994;51:896–900.Google Scholar
97. Paganini-Hill, A, Henderson, VW. Estrogen deficiency and risk ofAlzheimer’s disease in women. Am J Epidemiol 1994;140:256–261.Google Scholar
98. Paganini-Hill, A, Henderson, VW. Estrogen replacement therapyand risk of Alzheimer’s disease. Arch Intern Med 1996;156:2213–2217.Google Scholar
99. Tang, MX, Jacobs, D, Stern, Y, et al. Effect of oestrogen duringmenopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.Google Scholar
100. Haskell, SG, Richardson, ED, Horwitz, RI. The effect of estrogenreplacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 1997;50:1249–1264.Google Scholar
101. Schneider, LS, Farlow, MR, Henderson, VW, Pogoda, JM. Effects ofestrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 1996;46:1580–1584.Google Scholar
102. Mulnard, RA, Cotman, CW, Kawas, C, et al. Estrogen replacementtherapy for treatment of mild to moderate Alzheimer’s disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000;283:1007–1015.Google Scholar
103. Psaty, BM, Lee, M, Savage, JP, et al. Assessing the use ofmedications in the elderly: methods and initial experience in theCardiovascular Health Study. J Clin Epidemiol 1992;45:683–692.Google Scholar
104. Berger, AK, Fratiglioni, L, Forsell, Y, Winblad, B, Backman, L. Theoccurrence of depressive symptoms in the preclinical phase ofAD: a population-based study. Neurology 1999;53:1998–2002.Google Scholar
105. Devanand, DP, Sano, M, Tang, MX, et al. Depressed mood and theincidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry 1996;53:175–182.Google Scholar
106. Orgogozo, JM, Dartigues, JF, Lafont, S, et al. Wine consumption anddementia in the elderly: a prospective community study in theBordeaux area. Rev Neurol (Paris) 1997;153:185–192.Google Scholar
107. Gorelick, PB, Erkinjuntti, T, Hofman, A, et al. Prevention of vasculardementia. Alzheimer Dis Assoc Disord 1999;13 Suppl 3:S131–S139.Google Scholar
108. Whitlock, G, MacMahon, S, Anderson, C, Neal, B, Rodgers, A,Chalmers, J. Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Clin Exp Hypertens 1997;19: 843–855.Google Scholar
109. Snowdon, DA, Greiner, LH, Mortimer, JA, et al. Brain infarction andthe clinical expression of Alzheimer’s disease. JAMA 1997;277:813–817.Google Scholar
110. Gorelick, PB. Status of risk factors for dementia associated withstroke. Stroke 1997;28:459–463.CrossRefGoogle Scholar
111. Tatemichi, TK, Paik, M, Bagiella, E, et al. Risk of dementia afterstroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994;44:1885–1891.Google Scholar
112. Meyer, JS, McClintic, KL, Rogers, RL, Sims, P, Mortel, KF. Aetiological considerations and risk factors for multi-infarct dementia. J Neurol Neurosurg Psychiatry 1988;51:1489–1497.Google Scholar
113. Lindsay, J, Hebert, R, Rockwood, K. The Canadian Study of Healthand Aging: risk factors for vascular dementia. Stroke 1997;28:526–530.Google Scholar
114. Hulette, CM, McKeel, D, Morris, JC, et al. Clinical-neuropathologicfindings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997;48:668–672.Google Scholar
115. Havlik, RJ. Antihypertensive drugs, brain structure and cognitivefunction: More research is necessary. J Am Geriatr Soc 1997;45:1529–1531.Google Scholar
116. Maxwell, CJ, Hogan, DB, Ebly, EM. Calcium-channel blockers andcognitive function in elderly people: results from the Canadian Study of Health and Aging [published erratum appears in CMAJ 1999;161(11):1396]. CMAJ 1999;161:501–506.Google Scholar
117. Rockwood, K, Ebly, E, Hachinski, V, Hogan, D. Presence andtreatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurology 1997;54:33–39.Google Scholar
118. Erkinjuntti, T, Ketonen, L, Sulkava, R, Vuorialho, M, Palo, J. CT inthe differential diagnosis between Alzheimer’s disease and vascular dementia. Acta Neurol Scand 1987;75:262–270.CrossRefGoogle Scholar
119. Forette, F, Seux, ML, Staessen, JA, et al. Prevention of dementia inrandomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–1351.Google Scholar
120. Forette, F, Rigaud, AS, Seux, ML, et al. Reduction of dementia bycalcium-antagonist-based antihypertensive treatment. Eur Heart J Suppl 2000;2:D17–D19Google Scholar
121. Curb, JD, Pressel, SL, Cutler, JA, et al. Effect of diuretic-basedantihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886–1892.Google Scholar
122. Skoog, I. Vascular aspects in Alzheimer’s disease [In ProcessCitation]. J Neural Transm Suppl 2000;59:37–43.Google Scholar
123. The Canadian Cooperative Study Group. A randomized trial ofaspirin and sulfinpyrazone in threatened stroke. New Eng J Med 1978;299:53–59.Google Scholar
124. The SALT Collaborative Group. Swedish aspirin low-dose trial(SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345–1349.Google Scholar
125. International Stroke Trial Collaborative Group. The InternationalStroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acuteischaemic stroke. Lancet 1997;349:1569–1581.Google Scholar
126. Antiplatelet Trialists’ Collaboration. Collaborative overview ofrandomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.Google Scholar
127. Gent, M, Blakely, JA, Easton, JD, et al. The Canadian AmericanTiclopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.Google Scholar
128. CAPRIE Steering Committee. A randomised, blinded, trial ofclopidogrel versus asprin in patients at risk of ischaemic events(CAPRIE). Lancet 1996;348:1329–1339.Google Scholar
129. Diener, HC, Cunha, L, Forbes, C, et al. European Stroke PreventionStudy. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.Google Scholar
130. Albers, GW, Sherman, DG, Gress, DR, Paulseth, JE, Petersen, P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991;30:511–518.Google Scholar
131. North American Symptomatic Carotid Endarterectomy TrialCollaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New EngJ Med 1991;325:445–453.Google Scholar
132. Barnett, HJ, Taylor, DW, Eliasziw, M, et al. Benefit of carotidendarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415–1425.Google Scholar
133. ExecutiveCommitteefortheAsymptomatic CarotidAtherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421–1428.Google Scholar
134. European Pentoxifylline Multi-Infarct Dementia Study. Europeanpentoxifylline mulit-infarct dementia study. Eur Neurol 1996;36:315–321.Google Scholar
135. Parnetti, L, Senin, U, Carosi, M, Baasch, H. Mental deterioration inold age: results of two multicenter, clinical trials with nimodipine. The Nimopidine Study Group. Clin Ther 1993;15: 394–406.Google Scholar
136. Schneider, LS, Olin, JT. Overview of clinical trials of hydergine indementia. Arch Neurol 1994;51:787–798.Google Scholar
137. Kittner, B, Rossner, M, Rother, M. Clinical trials in dementia withpropentofylline. Ann NYAcad Sci 1997;826:307–316.Google Scholar
138. Kanowski, S, Herrmann, WM, Stephan, K, Wierich, W, Horr, R. Proofof efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47–56.Google Scholar
139. Meyer, JS, Rogers, RL, McClintic, K, Mortel, KF, Lotfi, J. Randomized clinical trial of daily aspirin therapy in multi- infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549–555.Google Scholar
140. Blume, J, Ruhlmann, KU, de la Haye, R, Rettig, K, Oltmer, G. Vascular-induced disorders of cerebral performance in the elderly. Long-term therapy with pentoxifylline and psychological mental training. Fortschr Med 1990;108:638–642.Google Scholar
141. Grundman, M. Vitamin E and Alzheimer’s disease: the basis foradditional clinical trials. Am J Clin Nutr 2000;71:630S–636S.Google Scholar
142. Sano, M, Ernesto, C, Thomas, RG, et al. A controlled trial ofselegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. New Eng J Med 1997;336:1216–1222.Google Scholar
143. Le Bars, PL, Katz, MM, Berman, N, et al. A placebo-controlled,double-blind, randomized trial of an extract of ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327–1332.Google Scholar
144. Neary, D, Snowden, JS, Gustafson, L, et al. Frontotemporal lobardegeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.Google Scholar
145. McKeith, IG, Galasko, D, Kosaka, K, et al. Consensus guidelines forthe clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology 1996;47:1113–1124.Google Scholar